Fiche publication
Date publication
juin 2012
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GARNACHE-OTTOU Francine
,
Pr SEILLES Estelle
,
Dr PERRUCHE Sylvain
,
Dr ANGELOT-DELETTRE Fanny
Tous les auteurs :
Saas P, Angelot F, Bardiaux L, Seilles E, Garnache-Ottou F, Perruche S
Lien Pubmed
Résumé
Labile blood products contain phosphatidylserine-expressing cell dusts, including apoptotic cells and microparticles. These cell by-products are produced during blood product process or storage and derived from the cells of interest that exert a therapeutic effect (red blood cells or platelets). Alternatively, phosphatidylserine-expressing cell dusts may also derived from contaminating cells, such as leukocytes, or may be already present in plasma, such as platelet-derived microparticles. These cell by-products present in labile blood products can be responsible for transfusion-induced immunomodulation leading to either transfusion-related acute lung injury (TRALI) or increased occurrence of post-transfusion infections or cancer relapse. In this review, we report data from the literature and our laboratory dealing with interactions between antigen-presenting cells and phosphatidylserine-expressing cell dusts, including apoptotic leukocytes and blood cell-derived microparticles. Then, we discuss how these phosphatidylserine-expressing cell by-products may influence transfusion.
Référence
Transfus Clin Biol. 2012 Jun;19(3):90-7
